

**Beneficiary Information**

1. Beneficiary Last Name: \_\_\_\_\_ 2. First Name: \_\_\_\_\_  
3. Beneficiary ID #: \_\_\_\_\_ 4. Beneficiary Date of Birth: \_\_\_\_\_ 5. Beneficiary Gender: \_\_\_\_\_

**Prescriber Information**

6. Prescriber Name: \_\_\_\_\_ NPI #: \_\_\_\_\_  
Mailing address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ ZIP: \_\_\_\_\_  
7. Requester Contact Information: \_\_\_\_\_  
Name: \_\_\_\_\_ Phone #: \_\_\_\_\_ Fax #: \_\_\_\_\_

**Drug Information**

8. Drug Name: \_\_\_\_\_ 9. Strength: \_\_\_\_\_ 10. Quantity Per 28 Days: 28  
11. Length of Therapy: 12 weeks

**Clinical Information**

1. Is the beneficiary 18 years of age or older with a diagnosis of chronic Hepatitis C (CHC) infection with confirmed genotype 1, 2, 3, 4, 5, or genotype 6 without cirrhosis or with compensated cirrhosis? Yes\_\_\_ No\_\_\_  
Genotype is: \_\_\_\_\_ Child-Pugh Grade: \_\_\_\_\_  
2. Has the beneficiary previously been treated with an HCV regimen containing an NS5A inhibitor and have a genotype of 1, 2, 3, 4, 5, or 6; or has the beneficiary previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor and has a genotype of 1a or genotype 3? Yes\_\_\_ No\_\_\_  
3. As the provider, are you reasonably certain that treatment will improve the beneficiary's overall health status? Yes\_\_\_ No\_\_\_  
4. Does the beneficiary have an FDA-labeled contraindication to Vosevi? Yes\_\_\_ No\_\_\_

Signature of Prescriber: \_\_\_\_\_

Date: \_\_\_\_\_

**\*Prescriber signature mandatory**

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.